FDA releases interchangeability guidance

In long-anticipated draft guidance on interchangeability of biosimilars, FDA said it will require most biosimilars' sponsors to conduct studies showing that switching between a biosimilar and its reference product poses no greater risk than continuing to use the

Read the full 387 word article

User Sign In